HC Wainwright & Co. Maintains Buy on Nektar Therapeutics, Raises Price Target to $185
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Arthur He maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $165 to $185.
HC Wainwright & Co. analyst Arthur He maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $165 to $185.